Comparison between therapeutic effects of low-dose simvastatin and mesenchymal stem cells (MSCs) transplantation on diabetic wound healing

Authors

  • Supakanda Sukpat Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Nipan Israsena Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Suthiluk Patumraj Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Keywords:

Diabetic wound, simvastatin, mesenchymal stem cells (MSCs)

Abstract

Background: Non-healing diabetic ulcers are the most common cause of amputation. Several studies have reported for the therapeutic potency of simvastatin and mesenchymal stem cells (MSCs) on improving angiogenic factors and wound healing.

Objectives: This study is aimed to evaluate and compare the treatment outcomes between low-dose simvastatin and MSCs transplantation in diabetic wound healing.

Methods: Balb/c nude mice were divided into four groups: control group (CON), diabetic wounded group (DM, streptozotocin 45 mg/kg intraperitoneal daily for 5 days), diabetic wounded group with daily oral treatment of simvastatin (DM+SIM) and diabetic wounded group with implanted MSCs (DM+MSCs). Seven days before wound creation, oral simvastatin was started in DM+SIM (0.25mg/kg/day). Eleven weeks after the diabetic induction, all mice were created bilateral full-thickness excisional skin wounds on the back and received fibrin gel or MSCs into wound bed. At day 7 and 14 post wounding, the percentage of wound closure (%WC), the percentage of capillary vascularity (%CV), tissue malondialdehyde (MDA) levels, stromal cell-derived factor 1 (SDF-1) levels, neutrophil infiltration and re-epithelialization were determined by using image analysis, confocal fluorescence microscopy, TBARs assay, immunohistochemically staining and hematoxylin and eosin staining, respectively. Interleukin 6 (IL-6) levels, tissue vascular endothelial growth factor (VEGF) levels, and pAkt levels were determined by using enzyme-linked immunosorbent assay.

Results: The %WC in DM+SIM and DM+MSCs groups were significantly higher when compared to the diabetic group. This study also showed that simvastatin and MSCs could increase %CV, VEGF, pAkt and SDF-1 level. Moreover, tissue MDA, IL-6 and neutrophil infiltration in DM+SIM and DM+MSCs groups were significantly decreased when compared to the diabetic group. Furthermore, the re-epithelialization of DM+MSCs group was significantly increased when compared to the diabetic group.

Conclusion: The results showed no significant difference between groups in all parameters on day 14 post-wound creation. Therefore, low-dose simvastatin might be used as an alternative treatment for diabetic wound healing.

Downloads

Download data is not yet available.

References

Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40-50. https://doi.org/10.1016/j.diabres.2017.03.024

Schreiber J, Efron PA, Park JE, Moldawer LL, Barbul A. Adenoviral gene transfer of an NF-kappaB superrepressor increases collagen deposition in rodent cutaneous wound healing. Surgery 2005;138:940-6. https://doi.org/10.1016/j.surg.2005.05.020

Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513-21. https://doi.org/10.2337/diacare.13.5.513

Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2008;2:313-9. https://doi.org/10.1016/j.stem.2008.03.002

Yan J, Tie G, Wang S, Messina KE, DiDato S, Guo S, et al. Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice. J Am Heart Assoc 2012;1:e002238. https://doi.org/10.1161/JAHA.112.002238

Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648-59. https://doi.org/10.1634/stemcells.2007-0226

Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: Improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003;75:204-9. https://doi.org/10.1016/S0003-4975(02)04291-1

Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004;117:3-10.

https://doi.org/10.1016/j.regpep.2003.09.005

Liang X, Su YP, Kong PY, Zeng DF, Chen XH, Peng XG, et al. Human bone marrow mesenchymal stem cells expressing SDF-1 promote hematopoietic stem cell function of human mobilised peripheral blood CD34+ cells in vivo and in vitro. Int J Radiat Biol 2010; 86:230-7.

https://doi.org/10.3109/09553000903422555

Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (mscs): Role as guardians of inflammation. Mol Ther 2012;20:14-20. https://doi.org/10.1038/mt.2011.211

Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab 2015;19:554-62. https://doi.org/10.4103/2230-8210.163106

Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003;24:225-48. https://doi.org/10.1016/S0195-668X(02)00419-0

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/American heart association task force on practice guidelines. Circulation 2014;129:S1-45. https://doi.org/10.1161/01.cir.0000437738.63853.7a

Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10. https://doi.org/10.1038/79510

Bitto A, Minutoli L, Altavilla D, Polito F, Fiumara T, Marini H, et al. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Pharmacol Res 2008;57:159-69. https://doi.org/10.1016/j.phrs.2008.01.005

Zhou B, Cao XC, Fang ZH, Zheng CL, Han ZB, Ren H, et al. Prevention of diabetic microangiopathy by prophylactic transplant of mobilized peripheral blood mononuclear cells. Acta Pharmacol Sin 2007;28:89-97. https://doi.org/10.1111/j.1745-7254.2007.00476.x

Sivan-Loukianova E, Awad OA, Stepanovic V, Bickenbach J, Schatteman GC. Cd34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J Vasc Res 2003;40:368-77.

https://doi.org/10.1159/000072701

Yang YJ, Qian HY, Huang J, Li JJ, Gao RL, Dou KF, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009;29:2076-82. https://doi.org/10.1161/ATVBAHA.109.189662

Greer JJ, Kakkar AK, Elrod JW, Watson LJ, Jones SP, Lefer DJ. Low-dose simvastatin improves survival and ventricular function via enos in congestive heart failure. Am J Physiol Heart Circ Physiol 2006;291:H2743-51. https://doi.org/10.1152/ajpheart.00347.2006

Marketou ME, Zacharis EA, Nikitovic D, Ganotakis ES, Parthenakis FI, Maliaraki N, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects. Angiology 2006;57:211-8. https://doi.org/10.1177/000331970605700212

Somchaichana J, Bunaprasert T, Patumraj S. Acanthus ebracteatus vahl. Ethanol extract enhancement of the efficacy of the collagen scaffold in wound closure: A study in a full-thickness-wound mouse model. J Biomed Biotechnol 2012;2012:754527. https://doi.org/10.1155/2012/754527

Badr G, Badr BM, Mahmoud MH, Mohany M, Rabah DM, Garraud O. Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1, MIP-2, KC, CX3CL1 and TGF- in wounded tissue. BMC Immunol 2012;13:32.

https://doi.org/10.1186/1471-2172-13-32

Yeh CC, Li H, Malhotra D, Turcato S, Nicholas S, Tu R, et al. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 2010;109:1185-91.

https://doi.org/10.1002/jcb.22498

Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 2003;46:1402-7.

https://doi.org/10.1007/s00125-003-1194-5

Garcia C, Feve B, Ferre P, Halimi S, Baizri H, Bordier L, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes Metab 2010;36:327-38.

https://doi.org/10.1016/j.diabet.2010.07.001

Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736-43.

https://doi.org/10.1016/S0140-6736(05)67700-8

Sukpat S, Israsena N, Patumraj S. Pleiotropic effects of simvastatin on wound healing in diabetic mice. J Med Assoc Thai 2016;99:213-9.

Rego AC, Araujo Filho I, Damasceno BP, Egito ES, Silveira IA, Brandao-Neto J, et al. Simvastatin improves the healing of infected skin wounds of rats. Acta Cir Bras 2007;22 Suppl 1:57-63.

https://doi.org/10.1590/S0102-86502007000700012

Asai J, Takenaka H, Hirakawa S, Sakabe J, Hagura A, Kishimoto S, et al. Topical simvastatin accelerates wound healing in diabetes by enhancing angiogenesis and lymphangiogenesis. Am J Pathol 2012;181:2217-24. https://doi.org/10.1016/j.ajpath.2012.08.023

Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, Kozawa O. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol 2004;43:333-40. https://doi.org/10.1097/00005344-200403000-00002

Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105: 3017-24.

https://doi.org/10.1161/01.CIR.0000018166.84319.55

Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011;29:5-10. https://doi.org/10.1002/stem.556

Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids 2011;46:333-40. https://doi.org/10.1007/s11745-010-3517-x

Yang D, Han Y, Zhang J, Chopp M, Seyfried DM. Statins enhance expression of growth factors and activate the PI3K/Akt -mediated signaling pathway after experimental intracerebral hemorrhage. World J Neurosci 2012;2:74-80. https://doi.org/10.4236/wjns.2012.22011

Cui X, Chopp M, Zacharek A, Roberts C, Lu M, Savant-Bhonsale S, et al. Chemokine, vascular and therapeutic effects of combination simvastatin and BMSC treatment of stroke. Neurobiol Dis 2009;36:35-41. https://doi.org/10.1016/j.nbd.2009.06.012

Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-9. https://doi.org/10.2337/diabetes.53.1.195

Cowled PA, Khanna A, Laws PE, Field JB, Varelias A, Fitridge RA. Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury. J Surg Res 2007;141:267-76. https://doi.org/10.1016/j.jss.2006.11.021

Karadeniz Cakmak G, Irkorucu O, Ucan BH, Emre AU, Bahadir B, Demirtas C, et al. Simvastatin improves wound strength after intestinal anastomosis in the rat. J Gastrointest Surg 2009;13:1707-16.

https://doi.org/10.1007/s11605-009-0951-2

Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-25.

https://doi.org/10.1016/S1074-7613(00)80334-9

Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9. https://doi.org/10.1161/01.ATV.0000022694.16328.CC

Downloads

Published

2023-08-03

How to Cite

1.
Sukpat S, Israsena N, Patumraj S. Comparison between therapeutic effects of low-dose simvastatin and mesenchymal stem cells (MSCs) transplantation on diabetic wound healing. Chula Med J [Internet]. 2023 Aug. 3 [cited 2024 Oct. 8];64(4). Available from: https://he05.tci-thaijo.org/index.php/CMJ/article/view/251